HB9061, the PREEMPT Act, would direct the Secretary of Health and Human Services to issue guidance to states on Medicaid and CHIP coverage of tests used for the screening and early detection of preeclampsia. The bill requires HHS to identify best practices for improving outcomes for pregnant women with preeclampsia and to explain which tests may be covered as medical assistance under state Medicaid plans or state child health plans, including advanced biomarker tests.
The bill also requires HHS to provide technical assistance to states that request help determining whether a particular preeclampsia detection test may be covered, and it clarifies that states are not required to seek such assistance as a condition of coverage or federal matching funds. In defining the tests to be considered, the bill specifically includes FDA-regulated devices and certain laboratory-developed tests performed by certified high-complexity clinical laboratories.
The bill would amend title XIX of the Social Security Act by adding a new section governing Medicaid and CHIP coverage guidance for preeclampsia screening and detection. It does not mandate that states cover any specific test, but it would shape state coverage decisions by requiring federal guidance and optional technical assistance on what tests may qualify for reimbursement, potentially affecting Medicaid managed care organizations, state child health plans, pregnant beneficiaries, and laboratories offering biomarker-based diagnostics.
The available context suggests generally favorable sentiment toward the bill, with bipartisan sponsorship and no recorded committee opposition or vote history in the materials provided. The findings section frames preeclampsia as a serious maternal health issue with significant mortality, racial disparities, and economic costs, indicating the bill is presented as a public health and maternal safety measure rather than a controversial coverage expansion.
The main policy issue is not whether preeclampsia is serious, but how far federal guidance should go in influencing state Medicaid and CHIP coverage of emerging diagnostic tests, especially biomarker tests and laboratory-developed tests. Potential points of contention include the evidentiary standard for coverage, the role of FDA-regulated versus lab-developed tests, and whether federal guidance could indirectly pressure states to cover services without an explicit mandate. No specific opposition is documented in the provided record.